What is the most recent evidence regarding use of cranberry products and efficacy for UTI prevention?

Comment by InpharmD Researcher

Published evidence supports cranberry products for preventing urinary tract infections (UTIs) in women with recurrent UTIs, with systematic reviews also reporting benefit in children and individuals susceptible to UTIs following interventions. Current AUA/CUA/SUFU guidelines recommend offering cranberry as an option for prophylaxis in women with recurrent UTIs, classified as a moderate recommendation with Grade B evidence. However, individual trial results vary, and pooled evidence does not support use in institutionalized older adults, pregnant women, or adults with neuromuscular bladder dysfunction and incomplete bladder emptying. Although some analyses report benefit with proanthocyanidin intake ≥36 mg/day, the optimal dose, formulation, and duration remain uncertain, with interpretation limited by variable product composition, differing UTI definitions, and study limitations; reported adverse events were generally mild.
Background

A 2025 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/CUA/SUFU) guideline update recommends that clinicians offer cranberry as an option for prophylaxis in women with recurrent urinary tract infections (UTIs), classified as a moderate recommendation with Grade B evidence. The guideline describes proanthocyanidins (PACs) as the proposed mediators of cranberry’s ability to prevent bacterial adhesion to the urothelium. A cited meta-analysis supports cranberry supplements standardized to at least 36 mg of PACs, reporting greater effectiveness in reducing UTI recurrence than products containing less than 36 mg; however, many commercial products lack documented validation of PAC dosage. Two recent randomized controlled trials involving 218 participants demonstrated reduced UTI rates with cranberry prophylaxis compared with placebo. Additionally, a 2024 systematic review and network meta-analysis of 20 trials involving more than 3,000 participants compared cranberry juice, cranberry tablets, and increased fluid intake for UTI prevention and management. As summarized in the guideline, cranberry juice consumption was associated with a 54% lower UTI rate, reduced antibiotic use by up to 50%, and significantly fewer UTI symptoms compared with no treatment. Although clinical studies have not routinely reported adverse effects, the guideline states that available evidence suggests minimal potential harms from cranberry use. [1]

A 2023 Cochrane systematic review of 50 randomized or quasi-randomized trials involving 8,857 participants evaluated cranberry products for preventing UTIs, with searches conducted through March 13, 2023. Compared with placebo, water, or no specific treatment, cranberry products reduced the risk of symptomatic, culture-verified UTIs (26 studies; 6,211 participants; risk ratio [RR] 0.70; 95% confidence interval [CI] 0.58 to 0.84; I²= 69%; moderate-certainty evidence). Subgroup analyses demonstrated reduced risk in women with recurrent UTIs (8 studies; 1,555 participants; RR 0.74; 95% CI 0.55 to 0.99; moderate-certainty evidence), children (5 studies; 504 participants; RR 0.46; 95% CI 0.32 to 0.68; moderate-certainty evidence), and individuals susceptible to UTIs following an intervention (6 studies; 1,434 participants; RR 0.47; 95% CI 0.37 to 0.61; low-certainty evidence). However, cranberry products may provide little or no benefit in institutionalized older adults (3 studies; 1,489 participants; RR 0.93; 95% CI 0.67 to 1.30), pregnant women (3 studies; 765 participants; RR 1.06; 95% CI 0.75 to 1.50), or adults with neuromuscular bladder dysfunction and incomplete bladder emptying (3 studies; 464 participants; RR 0.97; 95% CI 0.78 to 1.19). Compared with antibiotic prophylaxis, cranberry products may make little or no difference in symptomatic, culture-verified UTI risk (2 studies; 385 participants; RR 1.03; 95% CI 0.80 to 1.33). Gastrointestinal adverse events probably differed little or not at all between cranberry and placebo or no specific treatment (10 studies; 2,166 participants; RR 1.33; 95% CI 1.00 to 1.77; moderate-certainty evidence). Evidence was insufficient to determine whether efficacy differed between cranberry juice and tablets or between different proanthocyanidin doses. The authors concluded that cranberry products reduce symptomatic, culture-verified UTIs in women with recurrent UTIs, children, and individuals susceptible to UTIs following interventions; available evidence did not support their use in the other populations evaluated. [2]

A 2024 network meta-analysis of 20 controlled trials (18 randomized and 2 nonrandomized; 3,091 participants, 88.8% female) evaluated cranberry juice, cranberry tablets, and other liquids for UTI prevention. In the network meta-analysis of 18 studies reporting UTI rates, cranberry juice reduced the rate of UTIs by 27% compared with placebo liquid (rate ratio 0.73; 95% CI 0.59 to 0.91; p= 0.005; moderate-certainty evidence) and by 54% compared with no treatment (rate ratio 0.46; 95% CI 0.31 to 0.68; p<0.0001; very-low-certainty evidence). Excluding one study at high risk of bias reduced the estimated reduction versus no treatment from 54% to 49%. Evidence was insufficient to establish differences in UTI rates between cranberry tablets and placebo liquid, no treatment, or cranberry juice. A separate network meta-analysis of six studies found lower antibiotic use with cranberry juice versus placebo liquid (rate ratio 0.51; 95% CI 0.30 to 0.87; p= 0.014). The authors concluded that the evidence supports cranberry juice for UTI prevention; limitations included variation in definitions of recurrent UTIs, lack of participant and personnel blinding in nine studies, educational interventions accompanying cranberry supplementation in some studies, and insufficient male participants to permit comparisons by sex. [3]

A 2024 meta-analysis of 10 randomized controlled trials involving 2,438 participants evaluated the effectiveness of cranberry products for preventing UTIs, with particular emphasis on daily proanthocyanidin (PAC) intake. Included populations comprised women with recurrent UTIs, patients undergoing surgery, nursing home and long-term care residents, and older hospitalized patients; follow-up ranged from 10 days to 48 weeks. Cranberry products included juice and capsules, and comparators included placebo, low-dose PACs, or standard management. Overall, cranberry products reduced UTI risk by 15% compared with controls (relative risk 0.85; 95% CI 0.76 to 0.96; p= 0.008). In analyses stratified by PAC intake, consumption of ≥36 mg/day reduced UTI risk by 18% (RR 0.82; 95% CI 0.69 to 0.98; p= 0.03), whereas intake of <36 mg/day did not significantly reduce risk (p= 0.39). Subgroup analyses identified a significant reduction with cranberry use for 12 to 24 weeks (RR 0.75; 95% CI 0.61 to 0.91; p= 0.004), which remained significant after Bonferroni correction; reductions were not statistically significant with use for <12 weeks or 24 to 48 weeks. Although the female-only subgroup initially demonstrated a significant reduction (RR 0.84; 95% CI 0.71 to 0.98), this finding did not remain significant after correction for multiple comparisons. Limitations included the limited number and sample sizes of eligible trials, variable study quality, losses to follow-up, and differing UTI definitions based on symptoms, urine cultures, or both. The authors concluded that PAC dose and duration of cranberry use warrant consideration and that larger, high-quality randomized trials are needed to further evaluate these factors. [4]

A 2022 narrative review investigated the use of cranberry products to reduce the recurrence (secondary prevention) of urinary tract infections (UTIs) in older patients. Six systematic review articles of patients with or without recurrent UTIs were included for analysis. All patients were older than 65 years, and most were female from age-care or hospital settings. Interventions greatly varied, including juice, capsules, extracts, and powder formulations. While all studies found some level of support for regular cranberry administration to reduce UTI recurrence versus placebo, one systematic review reported non-significant trends. Their analysis of 15 studies noted that each study was non-significant in reducing symptomatic UTI, and the authors could not support their use as prevention in older patients with urinary catheters. Some systematic reviews note that cranberry capsules demonstrate favorable efficacy, specifically twice daily consumption of cranberry capsules (containing at least 36 mg proanthocyanidins [PCAs]). Adverse event rates were generally mild. The narrative review offers some understanding of cranberry product trends but lacks statistical analysis to validate potential benefits. [5]

A 2021 meta-analysis reviewed the effects of cranberry as adjuvant therapy on the recurrence rate of urinary tract infections in susceptible groups. Among 23 included randomized controlled trials (RCTs; N= 3,979), 15 trials administered cranberry juice, one used both cranberry juice and cranberry tablets, and twelve used cranberry capsules, with daily cranberry amounts ranging from 0.4 to 194.4 g. A subgroup analysis based on the formulation of cranberry-containing products found a relative risk reduction of 35% in patients who used cranberry juice versus cranberry capsules or tablets (risk ratio [RR] 0.65; confidence interval [CI] 0.54 to 0.77). Researchers found 13 studies that evaluated the use of cranberry juice to prevent UTIs (RR 0.65; CI 0.54 to 0.77; I2= 33%) and 10 studies that assessed the same outcome with cranberry capsules or tablets (RR 0.8; CI 0.7 to 0.91; I2= 52.7%). Large volumes of cranberry juice are required, and the sugar content may lead to severe gastrointestinal issues; however, the authors still suggest cranberry in juice form may be more favorable than cranberry in capsules or tablets for the desired result. Throughout the evaluated studies, there was no consistency among the levels of PACs, the active ingredient of cranberry products, believed to provide UTI prevention. The proposed daily recommended dose of PACs is 36 mg. These findings may have led to inconsistencies in the results. Of note, the compiled results did not show a significant decrease in recurrent UTIs in patients with neuropathic bladder, pregnant patients, or elderly patients. [6]

According to a 2017 meta-analysis, cranberry may be effective in preventing UTI recurrence in generally healthy women. This analysis included data from seven randomized controlled trials conducted in healthy women at risk of UTI (N= 1,498). Results showed that cranberry reduced the risk of UTI by 26% (pooled RR 0.74; 95% CI 0.55 to 0.98). Overall, the studies were relatively small, with only two having more than 300 participants. Although the authors state that cranberry may be useful in recurrent UTI prevention, they also mention that larger high-quality studies are needed to confirm these findings. Similarly, there is a lack of robust data regarding the optimum dosage and formulation of cranberry-derived active compounds (i.e., juice, tablet, capsule, or powder) in this setting. [7]

A 2016 study discussed the need for an alternative prophylactic approach to antibiotics in the case of UTIs. This article further detailed the anti-adhesion properties of cranberry due to the PAC component and tested the PAC levels in seven commercially available cranberry supplements (formulation not specified). Four of the seven products showed no anti-adhesion. The other three products' PAC levels ranged from 4 mg/g to 175 mg/g, with the highest PAC level showing the most anti-adhesion. This article also noted that clinical trials in the past have determined that at least 36 mg of PAC is required to result in significant reductions in recurrent UTIs. Similarly, the variability in quality of supplements available to consumers should be recognized. [8]

Background References: [1] Ackerman AL, Bradley M, D'Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2026;215(1):3-12. doi:10.1097/JU.0000000000004723
[2] Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321. Published 2023 Nov 10. doi:10.1002/14651858.CD001321.pub7
[3] Moro C, Phelps C, Veer V, et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2024;10(6):947-957. doi:10.1016/j.euf.2024.07.002
[4] Xiong Z, Gao Y, Yuan C, Jian Z, Wei X. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr. 2024;11:1422121. Published 2024 Nov 28. doi:10.3389/fnut.2024.1422121
[5] Bryce MR, Bryce CJC. Cranberry products to reduce recurrence of urinary tract infections in older people: a narrative review. Asian Journal of Gerontology & Geriatrics. 2022;17(2):60-63. doi:10.12809/ajgg-2022-554-ra
[6] Xia JY, Yang C, Xu DF, Xia H, Yang LG, Sun GJ. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One. 2021;16(9):e0256992. Published 2021 Sep 2. doi:10.1371/journal.pone.0256992
[7] Fu Z, Liska D, Talan D, Chung M. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017;147(12):2282-2288. doi:10.3945/jn.117.254961
[8] Chughtai B, Thomas D, Howell A. Variability of commercial cranberry dietary supplements for the prevention of uropathogenic bacterial adhesion. Am J Obstet Gynecol. 2016;215(1):122-123. doi:10.1016/j.ajog.2016.03.046
Literature Review

A search of the published medical literature revealed 18 studies investigating the researchable question:

What is the most recent evidence regarding use of cranberry products and efficacy for UTI prevention?

Level of evidence

B - One high-quality study or multiple studies with limitations  Read more→



Please see Tables 1-18 for your response.


 

Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women

Design

Open-label, randomized controlled trial

N = 150

Objective

To determine whether recurrences of urinary tract infection (UTI) can be prevented with cranberry-lingonberry juice or with Lactobacillus GG drink

Study Groups

Cranberry-lingonberry (n = 50)

Lactobacillus (n = 50)

Control (n = 50)

Inclusion Criteria

Women who had a UTI caused by E. coli and were not taking antimicrobial prophylaxis

Exclusion Criteria

Taking postcoital antimicrobials

Methods

Patients were randomized to receive 50 mL of cranberry-lingonberry juice (7.5 g cranberry concentration/1.7 g lingonberry concentrate) daily for 6 months, 100 mL of Lactobacillus GG drink (4x1010 colony-forming units of Lactobacillus GG/100mL) five days a week for one year, or control.

Duration

Trial: 1993 to 1997

Intervention: 6 months to one year

Follow-up: 12 months

Outcome Measures

First recurrence of symptomatic UTI

Baseline Characteristics

 

Cranberry-lingonberry (n = 50)

Lactobacillus (n = 49)

Control (n = 50)

Age, years

32 ± 9.8 30 ± 11.8 29 ± 10.5

Intercourse frequency

Less than once/week

1-2 times/week

> 3 times/week 


16 (33%)

17 (35%)

16 (33%)


25 (51%)

11 (22%)

13 (27%)


13 (27%)

18 (38%)

17 (35%)

Intercourse during follow-up

Less than once/week

1-2 times/week

> 3 times/week


10 (23%)

19 (43%)

15 (34%)


9 (19%)

23 (49%)

15 (32%)


7 (15%)

20 (43%)

20 (43%)

Birth control during follow up 

39 (81%) 39 (81%) 38 (83%)

Pregnancy during follow up 

1 (2%) 2 (4%) 2 (4%)

Antimicrobials for UTI in past year

44 (90%) 41 (85%) 41 (85%)

UTI antimicrobial prophylaxis

Before intervention

During follow-up


10 (21%)

1 (2%)


8 (17%)

5 (10%)


5 (11%)

3 (6%)

Results

 

Cranberry-lingonberry (n = 50) Lactobacillus (n= 50) Control (n= 50)

Incidence density, per person-year at risk

E. coli

Other bacteria


0.45*

15 (71%)

6 (29%)

0.91

31 (79%)

8 (21%)

0.81

32 (84%)

6 (16%)

Occurrence of UTI during follow up

21 (21%) 39 (40%) 38 (39%)

*The difference between the cranberry and control groups was significant (95% confidence interval 0.03 to 0.68, p= 0.03).

Adverse Events

Common Adverse Events: occasional complaints about the cranberry juice's bitter taste

Serious Adverse Events: N/A

Percentage that Discontinued due to Adverse Events: N/A

Study Author Conclusions

Daily consumption of 50 mL of cranberry-lingonberry concentrate seems to reduce symptomatic Ureoccurrencesces in women compared to the control group.

InpharmD Researcher Critique

The trial was an open-label trial, which may limit the results due to bias. Additionally, the trial was stopped prematurely due to a stop in cranberry juice production. Further limitations include a small sample size and a generally younger patient population, potentially limiting the generalizability of the results. Women also self-recorded results, and only half of the subjects returned the compliance sheet.



Table 1 References:
[9] Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322(7302):1571. doi:10.1136/bmj.322.7302.1571

 

Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women

Design

Open-label, randomized controlled trial

N = 150

Objective

To determine whether recurrences of urinary tract infection (UTI) can be prevented with cranberry-lingonberry juice or with Lactobacillus GG drink

Study Groups

Cranberry-lingonberry (n = 50)

Lactobacillus (n = 50)

Control (n = 50)

Inclusion Criteria

Women who had a UTI caused by E. coli and were not taking antimicrobial prophylaxis

Exclusion Criteria

Taking postcoital antimicrobials

Methods

Patients were randomized to receive 50 mL of cranberry-lingonberry juice (7.5 g cranberry concentration/1.7 g lingonberry concentrate) daily for 6 months, 100 mL of Lactobacillus GG drink (4x1010 colony-forming units of Lactobacillus GG/100mL) five days a week for one year, or control.

Duration

Trial: 1993 to 1997

Intervention: 6 months to one year

Follow-up: 12 months

Outcome Measures

First recurrence of symptomatic UTI

Baseline Characteristics

 

Cranberry-lingonberry (n = 50)

Lactobacillus (n = 49)

Control (n = 50)

Age, years

32 ± 9.8 30 ± 11.8 29 ± 10.5

Intercourse frequency

Less than once/week

1-2 times/week

> 3 times/week 


16 (33%)

17 (35%)

16 (33%)


25 (51%)

11 (22%)

13 (27%)


13 (27%)

18 (38%)

17 (35%)

Intercourse during follow-up

Less than once/week

1-2 times/week

> 3 times/week


10 (23%)

19 (43%)

15 (34%)


9 (19%)

23 (49%)

15 (32%)


7 (15%)

20 (43%)

20 (43%)

Birth control during follow up 

39 (81%) 39 (81%) 38 (83%)

Pregnancy during follow up 

1 (2%) 2 (4%) 2 (4%)

Antimicrobials for UTI in past year

44 (90%) 41 (85%) 41 (85%)

UTI antimicrobial prophylaxis

Before intervention

During follow-up


10 (21%)

1 (2%)


8 (17%)

5 (10%)


5 (11%)

3 (6%)

Results

 

Cranberry-lingonberry (n = 50) Lactobacillus (n= 50) Control (n= 50)

Incidence density, per person-year at risk

E. coli

Other bacteria


0.45*

15 (71%)

6 (29%)

0.91

31 (79%)

8 (21%)

0.81

32 (84%)

6 (16%)

Occurrence of UTI during follow up

21 (21%) 39 (40%) 38 (39%)

*The difference between the cranberry and control groups was significant (95% confidence interval 0.03 to 0.68, p= 0.03).

Adverse Events

Common Adverse Events: occasional complaints about the cranberry juice's bitter taste

Serious Adverse Events: N/A

Percentage that Discontinued due to Adverse Events: N/A

Study Author Conclusions

Daily consumption of 50 mL of cranberry-lingonberry concentrate seems to reduce symptomatic Ureoccurrencesces in women compared to the control group.

InpharmD Researcher Critique

The trial was an open-label trial, which may limit the results due to bias. Additionally, the trial was stopped prematurely due to a stop in cranberry juice production. Further limitations include a small sample size and a generally younger patient population, potentially limiting the generalizability of the results. Women also self-recorded results, and only half of the subjects returned the compliance sheet.



Table 2 References:
[10] Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001;322(7302):1571. doi:10.1136/bmj.322.7302.1571

 

High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial.

Design

Randomized, controlled, double-blind clinical trial

N=145

Objective

To assess the efficacy of a high dose cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection

Study Groups

Low-dose group (n = 73)

High-dose group (n = 72)

Inclusion Criteria

Sexually active healthy women, aged 18 years and older, recent history of recurrent urinary tract infections (UTIs) defined as (≥ 2 UTIs in the past 6 months and/or ≥ 3 UTIs in the past 12 months and no consumption of cranberry product, polyphenol or antioxidant supplements in the last 2 weeks

Exclusion Criteria

Pregnancy, anticoagulant medication in the last month, known allergy or intolerance to cranberry and history of anatomical urogenital anomalies, urogenital tract surgery, acute or chronic renal failure, nephrolithiasis or intestinal diseases causing malabsorption

Methods

Patients were randomized to receive ether high-dose cranberry proanthocyanidins (PAC) in the form of two 18.5 mg cranberry capsules per day or low-dose PAC in the form of two 1 mg cranberry capsules per day for 24 weeks.

Duration

24 weeks

Outcome Measures

Primary: the number of symptomatic UTIs during the 24-week follow-up period

Secondary: symptomatic UTI with pyuria and symptomatic UTI with bacteriuria

Baseline Characteristics

 

Low-dose group PAC (n = 73)

High-dose group PAC (n = 72)

Age, years

32.5 ± 14.2 27.2 ± 8.8

Ethnicity

Caucasian

Non-Caucasian

Biracial

 

65 (89.0%)

6 (8.2%)

2 (2.7%)

 

65 (90.3%)

5 (6.9%)

2 (2.8%)

Number of episodes of UTI in the past 6 months:

1

2

3

4

≥ 5

 

13 (17.8%) 

34 (46.6%) 

17 (23.3%) 

6 (8.22%) 

3 (4.11%) 

 

8 (11.1%)

37 (51.4%)

16 (22.2%)

7 (9.7%)

4 (5.6%)

Number of episodes of UTI in the past 12 months:

2

3

4

≥ 5

 

13 (17.8%) 

22 (30.1%) 

11 (15.1%) 

27 (37.0%)  

 

7 (9.72%)

29 (40.3%)

15 (20.8%)

21 (26.17%)

Type of Contraception:

Hormonal contraception 

Spermicide 

Non-hormonal intrauterine device (IUD)

Condom 

None 

 

43 (58.9%)

1 (1.4%) 

7 (9.6%) 

17 (23.3%) 

5 (6.8%) 

 

53 (73.6%)

0

4 (5.6%)

11 (15.3%)

4 (5.6%)

Personal history of recurrent UTI:

< 1 year 

1–2 years  

3–5 years  

6–10 years 

> 10 years 

Missing data 

 

4 (8.2%) 

9 (18.4%) 

15 (30.6%) 

14 (28.6%) 

7 (14.3%) 

24 

 

2 (4.3%) 

12 (25.5%)

15 (31.9%)

10 (21.3%)

8 (17.0%)

25

Hydration (average liters of water per day):

Mean ± SD 

< 1 

≥ 1–2  

> 2–3 

≥ 3 

Missing data 

 

1.62 ± 0.75 

9 (15.8%) 

30 (52.6%) 

13 (22.8%) 

5 (8.8%) 

16 

 

1.81 ± 0.63 

4 (7.0%)

27 (47.4%)

23 (40.4%) 

3 (7.0%)

15

Alcohol consumption (per week):

< 1 

1–3 

> 4 

Missing data 

 

7 (12.7%)  

28 (50.9%) 

20 (36.4%) 

18 

 

15 (25.9%)

21 (36.2%)

22 (37.9%)

14

Non-smoker 

52 (91.2%) 

55 (94.8%)

Results

Endpoint

Low dose group (n = 73)

High dose group (n = 72)

Subjects reporting symptomatic UTI:

0 

1 

2 

3 

4 

5 

≥ 1 

Total symptomatic UTIs

 

34 (46.6%) 

26 (35.6%) 

8 (11.0%) 

4 (5.5%) 

0

1 (1.4%) 

39 (53.4%) 

59

 

41 (57.0%)

21 (29.2%)

7 (9.7%)

2 (2.8%)

1 (1.4%)

0

31 (43.1%) 

45

Symptomatic UTI with pyuria at 24 weeksa

0

1

2

3

4

≥ 1

Total symptomatic UTIs with pyuria

 

50 (68.5%) 

17 (23.3%) 

5 (6.8%) 

0

1 (1.4%) 

23 (31.5%) 

31

 

53 (73.6%) 

14 (19.4%)

4 (5.6%)

0

1 (1.4%)

19 (26.4%)

26

Symptomatic UTI with pyuria at 24 weeksb

0 

1 

2 

3 

4 

5 

≥ 1 

Total symptomatic UTIs with pyuria

 

39 (53.4%) 

23 (31.5%) 

6 (8.2%) 

4 (5.5%) 

0

1 (1.4%) 

34 (46.6%) 

52

 

45 (62.5%)  

18 (25.0%)

7 (9.7%)

1 (1.4%)

1 (1.4%)

0 

27 (37.5%)

39

Symptomatic UTI with bacteriuria at 24 weeksa

0 

1 

2 

≥ 1 

Total symptomatic UTIs with bacteriuria

 

55 (75.3%) 

17 (23.3%) 

1 (1.4%) 

18 (24.7%) 

19

 

63 (87.5%) 

7 (9.7%)

2 (2.8%)

9 (12.5%)

11

Subjects reporting symptomatic UTI with bacteriuria at 24 weeksb

0 

1

2 

3 

4 

≥ 1 

 

42 (57.5%) 

22 (30.1%) 

6 (8.2%) 

3 (4.1%) 

0

31 (42.5%) 

 

51 (70.8%)

15 (20.8%)

4 (5.6%)

1 (1.4%)

1 (1.4%)

21 (29.2%) 

aSymptomatic UTI episodes without urine sample were considered as no symptomatic UTI

bSymptomatic UTI episodes without urine sample were considered as symptomatic UTI

Adverse Events

Common Adverse Events: dyspepsia

Percentage that Discontinued due to Adverse Events: One participant from each group, 2/145 (1.4%).

Study Author Conclusions

High dose twice daily proanthocyanidin extract was not associated with a reduction in the number of symptomatic urinary tract infections when compared to a low dose proanthocyanidin extract. Our post-hoc results reveal that this high dose of proanthocyanidins may have a preventive impact on symptomatic urinary tract infection recurrence in women who experienced less than 5 infections per year.

InpharmD Researcher Critique

The use of a control low-dose PAC instead of a placebo might explain why there was no significant reduction in UTI recurrence between the two groups. Incomplete urine cultures and the exclusion of urine samples due to contamination caused by the improper clean-catch urine technique might have negatively influenced the outcomes of the study.



Table 3 References:
[11] Babar A, Moore L, Leblanc V, et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol. 2021;21(1):44. Published 2021 Mar 23. doi:10.1186/s12894-021-00811-w

 

High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial.

Design

Randomized, controlled, double-blind clinical trial

N=145

Objective

To assess the efficacy of a high dose cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection

Study Groups

Low-dose group (n = 73)

High-dose group (n = 72)

Inclusion Criteria

Sexually active healthy women, aged 18 years and older, recent history of recurrent urinary tract infections (UTIs) defined as (≥ 2 UTIs in the past 6 months and/or ≥ 3 UTIs in the past 12 months and no consumption of cranberry product, polyphenol or antioxidant supplements in the last 2 weeks

Exclusion Criteria

Pregnancy, anticoagulant medication in the last month, known allergy or intolerance to cranberry and history of anatomical urogenital anomalies, urogenital tract surgery, acute or chronic renal failure, nephrolithiasis or intestinal diseases causing malabsorption

Methods

Patients were randomized to receive ether high-dose cranberry proanthocyanidins (PAC) in the form of two 18.5 mg cranberry capsules per day or low-dose PAC in the form of two 1 mg cranberry capsules per day for 24 weeks.

Duration

24 weeks

Outcome Measures

Primary: the number of symptomatic UTIs during the 24-week follow-up period

Secondary: symptomatic UTI with pyuria and symptomatic UTI with bacteriuria

Baseline Characteristics

 

Low-dose group PAC (n = 73)

High-dose group PAC (n = 72)

Age, years

32.5 ± 14.2 27.2 ± 8.8

Ethnicity

Caucasian

Non-Caucasian

Biracial

 

65 (89.0%)

6 (8.2%)

2 (2.7%)

 

65 (90.3%)

5 (6.9%)

2 (2.8%)

Number of episodes of UTI in the past 6 months:

1

2

3

4

≥ 5

 

13 (17.8%) 

34 (46.6%) 

17 (23.3%) 

6 (8.22%) 

3 (4.11%) 

 

8 (11.1%)

37 (51.4%)

16 (22.2%)

7 (9.7%)

4 (5.6%)

Number of episodes of UTI in the past 12 months:

2

3

4

≥ 5

 

13 (17.8%) 

22 (30.1%) 

11 (15.1%) 

27 (37.0%)  

 

7 (9.72%)

29 (40.3%)

15 (20.8%)

21 (26.17%)

Type of Contraception:

Hormonal contraception 

Spermicide 

Non-hormonal intrauterine device (IUD)

Condom 

None 

 

43 (58.9%)

1 (1.4%) 

7 (9.6%) 

17 (23.3%) 

5 (6.8%) 

 

53 (73.6%)

0

4 (5.6%)

11 (15.3%)

4 (5.6%)

Personal history of recurrent UTI:

< 1 year 

1–2 years  

3–5 years  

6–10 years 

> 10 years 

Missing data 

 

4 (8.2%) 

9 (18.4%) 

15 (30.6%) 

14 (28.6%) 

7 (14.3%) 

24 

 

2 (4.3%) 

12 (25.5%)

15 (31.9%)

10 (21.3%)

8 (17.0%)

25

Hydration (average liters of water per day):

Mean ± SD 

< 1 

≥ 1–2  

> 2–3 

≥ 3 

Missing data 

 

1.62 ± 0.75 

9 (15.8%) 

30 (52.6%) 

13 (22.8%) 

5 (8.8%) 

16 

 

1.81 ± 0.63 

4 (7.0%)

27 (47.4%)

23 (40.4%) 

3 (7.0%)

15

Alcohol consumption (per week):

< 1 

1–3 

> 4 

Missing data 

 

7 (12.7%)  

28 (50.9%) 

20 (36.4%) 

18 

 

15 (25.9%)

21 (36.2%)

22 (37.9%)

14

Non-smoker 

52 (91.2%) 

55 (94.8%)

Results

Endpoint

Low dose group (n = 73)

High dose group (n = 72)

Subjects reporting symptomatic UTI:

0 

1 

2 

3 

4 

5 

≥ 1 

Total symptomatic UTIs

 

34 (46.6%) 

26 (35.6%) 

8 (11.0%) 

4 (5.5%) 

0

1 (1.4%) 

39 (53.4%) 

59

 

41 (57.0%)

21 (29.2%)

7 (9.7%)

2 (2.8%)

1 (1.4%)

0

31 (43.1%) 

45

Symptomatic UTI with pyuria at 24 weeksa

0

1

2

3

4

≥ 1

Total symptomatic UTIs with pyuria

 

50 (68.5%) 

17 (23.3%) 

5 (6.8%) 

0

1 (1.4%) 

23 (31.5%) 

31

 

53 (73.6%) 

14 (19.4%)

4 (5.6%)

0

1 (1.4%)

19 (26.4%)

26

Symptomatic UTI with pyuria at 24 weeksb

0 

1 

2 

3 

4 

5 

≥ 1 

Total symptomatic UTIs with pyuria

 

39 (53.4%) 

23 (31.5%) 

6 (8.2%) 

4 (5.5%) 

0

1 (1.4%) 

34 (46.6%) 

52

 

45 (62.5%)  

18 (25.0%)

7 (9.7%)

1 (1.4%)

1 (1.4%)

0 

27 (37.5%)

39

Symptomatic UTI with bacteriuria at 24 weeksa

0 

1 

2 

≥ 1 

Total symptomatic UTIs with bacteriuria

 

55 (75.3%) 

17 (23.3%) 

1 (1.4%) 

18 (24.7%) 

19

 

63 (87.5%) 

7 (9.7%)

2 (2.8%)

9 (12.5%)

11

Subjects reporting symptomatic UTI with bacteriuria at 24 weeksb

0 

1

2 

3 

4 

≥ 1 

 

42 (57.5%) 

22 (30.1%) 

6 (8.2%) 

3 (4.1%) 

0

31 (42.5%) 

 

51 (70.8%)

15 (20.8%)

4 (5.6%)

1 (1.4%)

1 (1.4%)

21 (29.2%) 

aSymptomatic UTI episodes without urine sample were considered as no symptomatic UTI

bSymptomatic UTI episodes without urine sample were considered as symptomatic UTI

Adverse Events

Common Adverse Events: dyspepsia

Percentage that Discontinued due to Adverse Events: One participant from each group, 2/145 (1.4%).

Study Author Conclusions

High dose twice daily proanthocyanidin extract was not associated with a reduction in the number of symptomatic urinary tract infections when compared to a low dose proanthocyanidin extract. Our post-hoc results reveal that this high dose of proanthocyanidins may have a preventive impact on symptomatic urinary tract infection recurrence in women who experienced less than 5 infections per year.

InpharmD Researcher Critique

The use of a control low-dose PAC instead of a placebo might explain why there was no significant reduction in UTI recurrence between the two groups. Incomplete urine cultures and the exclusion of urine samples due to contamination caused by the improper clean-catch urine technique might have negatively influenced the outcomes of the study.



Table 4 References:
[12] Babar A, Moore L, Leblanc V, et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol. 2021;21(1):44. Published 2021 Mar 23. doi:10.1186/s12894-021-00811-w

 

Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial

Design

Randomized, double-blind, placebo-controlled trial

N= 160

Objective

To evaluate the therapeutic efficacy of cranberry juice capsules in preventing urinary tract infections (UTIs) after elective gynecological surgery in which a urinary catheter is placed

Study Groups

Placebo (n= 80)

Cranberry (n= 80)

Inclusion Criteria

Nonpregnant women, age ≥ 18 years

Exclusion Criteria

Allergy to cranberry products, requirement for therapeutic anticoagulant medicine during the 6 weeks after surgery or whose surgery involved a fistula repair or a vaginal mesh removal, a history of nephrolithiasis, congenital urogenital anomaly, or neurogenic bladder

Methods

Patients were randomized in a 1:1 ratio to receive two cranberry juice capsules 2 times a day (once in morning and once in evening), equivalent to two 8-ounce servings of cranberry juice, for 6 weeks after surgery or a matching placebo.

Patients were instructed to start at the time of discharge for 4-6 weeks, or until their return for their postoperative doctor’s visit, and were instructed to drink an 8 ounce glass of water while taking the capsule with or without food.

Duration

Trial: August 2011 to January 2013

Intervention: 6 weeks

Outcome Measures

Primary: proportion of participants who experienced clinically diagnosed and treated UTI

Secondary: incidence of UTI caused by E. coli, time from randomization to UTI

Baseline Characteristics

 

Placebo (n= 80)

Cranberry (n= 80)

 

Age, years

< 60 years

56

60%

56

59%

 

Race

Non-Hispanic white

Non-Hispanic black

Other or mixed race

 

88%

5%

7%

 

84%

5%

11%

 

Ever experienced UTI in life

63%

64%

 

Experienced UTI in the past 12 months

24% 23%  

Socio-demographic characteristics and most medical history features were not statistically significantly different between groups.

Results

Endpoint

Placebo (n= 80)

Cranberry (n= 80)

Odds ratio (95% confidence interval);p-value

Occurrence of UTI

Culture-confirmed

30 (38%)

23 (29%)

15 (19%)

12 (15%)

0.38 (0.19 to 0.79); p= 0.008

0.44 (0.20 to 0.96); p= 0.04

E. coli causing UTI

12 of 23 (46%) 5 of 12 (38%) 0.38* (0.13 to 1.13); p= 0.07

Median time to UTI, days

8.5 18 p= 0.0005

*Reflecting a reduction of 62% 

Adverse Events

No significant difference in incidence of adverse events was reported between groups. Adverse events were reported in 75 patients in the cranberry group vs. 78 patients in the placebo group. Severe adverse events were reported in 4 cranberry patients and 4 placebo patients. The most common adverse event overall was gastrointestinal upset (56% of patients in cranberry group vs. 61% of patients in placebo group). 

Study Author Conclusions

Among women undergoing elective benign gynecologic surgery involving urinary catheterization, use of cranberry extract tablets during the postoperative period reduced the rate of UTI by half

InpharmD Researcher Critique

Compared to previous trials, this study utilized cranberry capsules as opposed to juice. Use of capsules is thought to be associated with improved compliance, resulting in more reliable outcomes. Additionally, the use of placebo capsules in this study as opposed to placebo juice (which contained vitamin C) prevents confounding of results due to the presence of vitamin C in the placebo juice, which may impact UTI risk. 



Table 5 References:
[13] Foxman B, Cronenwett AE, Spino C, Berger MB, Morgan DM. Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial. Am J Obstet Gynecol. 2015;213(2):194.e1-194.e1948. doi:10.1016/j.ajog.2015.04.003

 

Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial

Design

Randomized, double-blind, placebo-controlled trial

N= 160

Objective

To evaluate the therapeutic efficacy of cranberry juice capsules in preventing urinary tract infections (UTIs) after elective gynecological surgery in which a urinary catheter is placed

Study Groups

Placebo (n= 80)

Cranberry (n= 80)

Inclusion Criteria

Nonpregnant women, age ≥ 18 years

Exclusion Criteria

Allergy to cranberry products, requirement for therapeutic anticoagulant medicine during the 6 weeks after surgery or whose surgery involved a fistula repair or a vaginal mesh removal, a history of nephrolithiasis, congenital urogenital anomaly, or neurogenic bladder

Methods

Patients were randomized in a 1:1 ratio to receive two cranberry juice capsules 2 times a day (once in morning and once in evening), equivalent to two 8-ounce servings of cranberry juice, for 6 weeks after surgery or a matching placebo.

Patients were instructed to start at the time of discharge for 4-6 weeks, or until their return for their postoperative doctor’s visit, and were instructed to drink an 8 ounce glass of water while taking the capsule with or without food.

Duration

Trial: August 2011 to January 2013

Intervention: 6 weeks

Outcome Measures

Primary: proportion of participants who experienced clinically diagnosed and treated UTI

Secondary: incidence of UTI caused by E. coli, time from randomization to UTI

Baseline Characteristics

 

Placebo (n= 80)

Cranberry (n= 80)

 

Age, years

< 60 years

56

60%

56

59%

 

Race

Non-Hispanic white

Non-Hispanic black

Other or mixed race

 

88%

5%

7%

 

84%

5%

11%

 

Ever experienced UTI in life

63%

64%

 

Experienced UTI in the past 12 months

24% 23%  

Socio-demographic characteristics and most medical history features were not statistically significantly different between groups.

Results

Endpoint

Placebo (n= 80)

Cranberry (n= 80)

Odds ratio (95% confidence interval);p-value

Occurrence of UTI

Culture-confirmed

30 (38%)

23 (29%)

15 (19%)

12 (15%)

0.38 (0.19 to 0.79); p= 0.008

0.44 (0.20 to 0.96); p= 0.04

E. coli causing UTI

12 of 23 (46%) 5 of 12 (38%) 0.38* (0.13 to 1.13); p= 0.07

Median time to UTI, days

8.5 18 p= 0.0005

*Reflecting a reduction of 62% 

Adverse Events

No significant difference in incidence of adverse events was reported between groups. Adverse events were reported in 75 patients in the cranberry group vs. 78 patients in the placebo group. Severe adverse events were reported in 4 cranberry patients and 4 placebo patients. The most common adverse event overall was gastrointestinal upset (56% of patients in cranberry group vs. 61% of patients in placebo group). 

Study Author Conclusions

Among women undergoing elective benign gynecologic surgery involving urinary catheterization, use of cranberry extract tablets during the postoperative period reduced the rate of UTI by half

InpharmD Researcher Critique

Compared to previous trials, this study utilized cranberry capsules as opposed to juice. Use of capsules is thought to be associated with improved compliance, resulting in more reliable outcomes. Additionally, the use of placebo capsules in this study as opposed to placebo juice (which contained vitamin C) prevents confounding of results due to the presence of vitamin C in the placebo juice, which may impact UTI risk. 



Table 6 References:
[14] Foxman B, Cronenwett AE, Spino C, Berger MB, Morgan DM. Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial. Am J Obstet Gynecol. 2015;213(2):194.e1-194.e1948. doi:10.1016/j.ajog.2015.04.003

 

Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial

Design

Randomized, placebo-controlled, double-blind trial

N = 376

Objective

To assess whether cranberry juice ingestion is effective in reducing UTIs in older people in hospital

Study Groups

Cranberry juice (n = 187)

Placebo (n = 189)

Inclusion Criteria

60 years or older, admitted in rehabilitation or acute settings, provided informed consent

Exclusion Criteria

Mental State Questionaire (MSQ) <5/10, dysphagia, UTI symptoms, received antibiotic treatment, length of stay <1 week, regular cranberry juice drinker, has an in-dwelling catheter, terminal illness, on warfarin during the final 8 weeks of recruitment

Methods

Patients were randomized to receive either 300 mL of cranberry juice (150 mL twice daily) or a placebo beverage. The juice was administered by nursing staff to optimize adherence. The juice contained water, cranberry juice from concentrate (25%), sugar, vitamin C, and non-nutritive sweetener (aspartame). The proanthocyanidin concentration was 11.175 mcg/g. The placebo beverage contained no cranberry solids but additionally contained elderberry extract.

Duration

Intervention duration: placebo = 21 days, cranberry juice = 24 days

Outcome Measures

Primary: first occurrence of symptomatic UTI (positive culture >104 cfu/mL)

Secondary: adherence to cranberry juice, antibiotics prescribed, organisms responsible for UTIs

Baseline Characteristics

 

Placebo group (n= 189)

Cranberry juice (n= 187)

   

Mean age, year

81.4  81.3    
Female 133 122    

Median number of medications per stay, range

8  7    

History of culture-positive urine in the past 12 months

48 53    

Results

 

Placebo group (n = 189)

Cranberry juice (n = 187)

Relative risk (RR) (95% confidence interval [CI])

p-Value

First occurrence of symptomatic UTI 

14 (7.4%)

7 (3.7%) 0.51 (0.21 to 1.222) 0.122
Adherence to cranberry juice, mL (interquartile range [IQR])

300 (44)

300 (28) -- 0.208
Antibiotic use

35 (19%)

32 (17%) -- 0.721
Infection caused by E. coli

13

4 0.31 (0.10 to 0.94) 0.027

Adverse Events

Thirteen events occurred (6 in placebo and 7 in the cranberry group) which all led to withdrawal from study. The events included gastrointestinal upset, rash, elevated blood glucose in a known diabetic, and death

Study Author Conclusions

This study has confirmed the acceptability of cranberry juice to older people. Larger trials are now required to determine whether it is effective in reducing UTIs in older hospital patients.

InpharmD Researcher Critique

Because the rate of infection observed was lower than anticipated, the study results were underpowered. The cranberry group received a slightly longer intervention period compared to placebo. Warfarin was added as an exclusion criteria during the final 8 weeks of the study due to a safety alert in the United Kingdom.



Table 7 References:
[15] McMurdo ME, Bissett LY, Price RJ, Phillips G, Crombie IK. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing. 2005;34(3):256-261. doi:10.1093/ageing/afi101

 

Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial

Design

Randomized, placebo-controlled, double-blind trial

N = 376

Objective

To assess whether cranberry juice ingestion is effective in reducing UTIs in older people in hospital

Study Groups

Cranberry juice (n = 187)

Placebo (n = 189)

Inclusion Criteria

60 years or older, admitted in rehabilitation or acute settings, provided informed consent

Exclusion Criteria

Mental State Questionaire (MSQ) <5/10, dysphagia, UTI symptoms, received antibiotic treatment, length of stay <1 week, regular cranberry juice drinker, has an in-dwelling catheter, terminal illness, on warfarin during the final 8 weeks of recruitment

Methods

Patients were randomized to receive either 300 mL of cranberry juice (150 mL twice daily) or a placebo beverage. The juice was administered by nursing staff to optimize adherence. The juice contained water, cranberry juice from concentrate (25%), sugar, vitamin C, and non-nutritive sweetener (aspartame). The proanthocyanidin concentration was 11.175 mcg/g. The placebo beverage contained no cranberry solids but additionally contained elderberry extract.

Duration

Intervention duration: placebo = 21 days, cranberry juice = 24 days

Outcome Measures

Primary: first occurrence of symptomatic UTI (positive culture >104 cfu/mL)

Secondary: adherence to cranberry juice, antibiotics prescribed, organisms responsible for UTIs

Baseline Characteristics

 

Placebo group (n= 189)

Cranberry juice (n= 187)

   

Mean age, year

81.4  81.3    
Female 133 122    

Median number of medications per stay, range

8  7    

History of culture-positive urine in the past 12 months

48 53    

Results

 

Placebo group (n = 189)

Cranberry juice (n = 187)

Relative risk (RR) (95% confidence interval [CI])

p-Value

First occurrence of symptomatic UTI 

14 (7.4%)

7 (3.7%) 0.51 (0.21 to 1.222) 0.122
Adherence to cranberry juice, mL (interquartile range [IQR])

300 (44)

300 (28) -- 0.208
Antibiotic use

35 (19%)

32 (17%) -- 0.721
Infection caused by E. coli

13

4 0.31 (0.10 to 0.94) 0.027

Adverse Events

Thirteen events occurred (6 in placebo and 7 in the cranberry group) which all led to withdrawal from study. The events included gastrointestinal upset, rash, elevated blood glucose in a known diabetic, and death

Study Author Conclusions

This study has confirmed the acceptability of cranberry juice to older people. Larger trials are now required to determine whether it is effective in reducing UTIs in older hospital patients.

InpharmD Researcher Critique

Because the rate of infection observed was lower than anticipated, the study results were underpowered. The cranberry group received a slightly longer intervention period compared to placebo. Warfarin was added as an exclusion criteria during the final 8 weeks of the study due to a safety alert in the United Kingdom.



Table 8 References:
[16] McMurdo ME, Bissett LY, Price RJ, Phillips G, Crombie IK. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing. 2005;34(3):256-261. doi:10.1093/ageing/afi101

 

Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women

Design

Randomized, active-controlled, double-blind trial

N= 137

Objective

To compare the effectiveness of cranberry extract with low-dose trimethoprim in the prevention of recurrent urinary tract infections (UTIs) in older women 

Study Groups

Cranberry (n= 69)

Trimethoprim (n= 68)

Inclusion Criteria

Women aged ≥ 45 years with at least two antibiotic-treated UTIs or confirmed episodes of cystitis in the previous 12 months confirmed by general practitioner (not necessarily confirmed by microbiological culture)

Exclusion Criteria

Previous urological surgery, stones or anatomical abnormalities of the urinary tract, urinary catheter, diabetes mellitus, immunocompromised, pyelonephritis, severe renal impairment, blood dyscrasias, symptomatic UTI at baseline, cognitive impairment, resident in institutional care, on long-term antibiotic therapy, on warfarin therapy, regular cranberry consumers, childbearing potential

Methods

Participants were randomized to receive either one capsule of 500 mg of cranberry extract (Cran-Max™) taken at bedtime for 6 months or one capsule of 100 mg of trimethoprim. Both sets of capsules were identical in appearance. Urine specimens were obtained from all participants at baseline and during follow-up visits for culture and susceptibility testing in participants presenting with symptoms of UTI. 

Duration

Duration: 6 months 

Follow-up: Home visits occurred at 3 and 6 months while participants were telephoned at 1, 2, 4, and 5 months to encourage adherence and record adverse events.

Outcome Measures

Primary: proportion of participants in each group experiencing a recurrence of an antibiotic-treated UTI and the time to first recurrence

Secondary: adherence to treatment 

Baseline Characteristics

 

Cranberry (n= 69)

Trimethoprim (n= 68)

   

Age, years

62.6 ± 10.8

63.3 ± 10.1

   

Median number of medications (range)

3 (0-13) 4 (0-11)    

Median length of history of UTIs, years (range)

11 (1-50) 18 (1-53)     

Median number of self-reported UTIs in past 12 months (range)

3 (2-15) 3 (2-8)     

Median number of antibiotic-treated UTIs in past 12 months (range)

3 (2-15) 2 (2-8)    

Bacteriuria at baseline

E. coli

K. pneumoniae

Streptococcus B

E. faecalis

5 (7.2%)

2

1

1

1

7 (10.3%)

6

0

1

0

   

Results

Endpoint

Cranberry (n= 69)

Trimethoprim (n= 68)

RR (95% CI)

p-value

Symptomatic antibiotic-treated UTI, n

25 14 1.616 (0.93-2.79) 0.084

Median time to first recurrence of UTI, days

84.5 91  N/A 0.479

Median adherence, % (range)

99 (25-149) 100 (66-112) N/A N/A

CI: confidence interval, RR: Relative Risk

Adverse Events

Common Adverse Events: non-UTI urinary symptoms (17% vs. 13%), gastrointestinal upset (13% vs. 19%), thrush (4% vs. 4%), colds/flu (6% vs. 6%)

Serious Adverse Events: abdominal abscess (1% vs. 0), breast carcinoma (1% vs. 0), shingles (0 vs. 1%), type II diabetes (0 vs. 1%)

Percentage that Discontinued due to Adverse Events: cranberry 6 (9%) vs. trimethoprim 11 (16%); p= 0.205

Study Author Conclusions

Trimethoprim had a very limited advantage over cranberry extract in the prevention of recurrent UTIs in older women and had more adverse effects. Our findings will allow older women with recurrent UTIs to weigh up with their clinicians the inherent attractions of a cheap, natural product like cranberry extract whose use does not carry the risk of antimicrobial resistance or super-infection with Clostridium difficile or fungi.

InpharmD Researcher Critique

The difference in occurrence of recurrent UTI in both groups was not statistically significant potentially due to a limited sample size. Additionally, this trial was specific to older women with a history of UTI, thus, potentially limiting generalizability. Further evidence may be needed to assess the benefits of cranberry in younger adults. Also, this study utilized an extract from cranberry rather than juice. 



Table 9 References:
[17] McMurdo ME, Argo I, Phillips G, Daly F, Davey P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. J Antimicrob Chemother. 2009;63(2):389-395. doi:10.1093/jac/dkn489

 

Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women

Design

Randomized, active-controlled, double-blind trial

N= 137

Objective

To compare the effectiveness of cranberry extract with low-dose trimethoprim in the prevention of recurrent urinary tract infections (UTIs) in older women 

Study Groups

Cranberry (n= 69)

Trimethoprim (n= 68)

Inclusion Criteria

Women aged ≥ 45 years with at least two antibiotic-treated UTIs or confirmed episodes of cystitis in the previous 12 months confirmed by general practitioner (not necessarily confirmed by microbiological culture)

Exclusion Criteria

Previous urological surgery, stones or anatomical abnormalities of the urinary tract, urinary catheter, diabetes mellitus, immunocompromised, pyelonephritis, severe renal impairment, blood dyscrasias, symptomatic UTI at baseline, cognitive impairment, resident in institutional care, on long-term antibiotic therapy, on warfarin therapy, regular cranberry consumers, childbearing potential

Methods

Participants were randomized to receive either one capsule of 500 mg of cranberry extract (Cran-Max™) taken at bedtime for 6 months or one capsule of 100 mg of trimethoprim. Both sets of capsules were identical in appearance. Urine specimens were obtained from all participants at baseline and during follow-up visits for culture and susceptibility testing in participants presenting with symptoms of UTI. 

Duration

Duration: 6 months 

Follow-up: Home visits occurred at 3 and 6 months while participants were telephoned at 1, 2, 4, and 5 months to encourage adherence and record adverse events.

Outcome Measures

Primary: proportion of participants in each group experiencing a recurrence of an antibiotic-treated UTI and the time to first recurrence

Secondary: adherence to treatment 

Baseline Characteristics

 

Cranberry (n= 69)

Trimethoprim (n= 68)

   

Age, years

62.6 ± 10.8

63.3 ± 10.1

   

Median number of medications (range)

3 (0-13) 4 (0-11)    

Median length of history of UTIs, years (range)

11 (1-50) 18 (1-53)     

Median number of self-reported UTIs in past 12 months (range)

3 (2-15) 3 (2-8)     

Median number of antibiotic-treated UTIs in past 12 months (range)

3 (2-15) 2 (2-8)    

Bacteriuria at baseline

E. coli

K. pneumoniae

Streptococcus B

E. faecalis

5 (7.2%)

2

1

1

1

7 (10.3%)

6

0

1

0

   

Results

Endpoint

Cranberry (n= 69)

Trimethoprim (n= 68)

RR (95% CI)

p-value

Symptomatic antibiotic-treated UTI, n

25 14 1.616 (0.93-2.79) 0.084

Median time to first recurrence of UTI, days

84.5 91  N/A 0.479

Median adherence, % (range)

99 (25-149) 100 (66-112) N/A N/A

CI: confidence interval, RR: Relative Risk

Adverse Events

Common Adverse Events: non-UTI urinary symptoms (17% vs. 13%), gastrointestinal upset (13% vs. 19%), thrush (4% vs. 4%), colds/flu (6% vs. 6%)

Serious Adverse Events: abdominal abscess (1% vs. 0), breast carcinoma (1% vs. 0), shingles (0 vs. 1%), type II diabetes (0 vs. 1%)

Percentage that Discontinued due to Adverse Events: cranberry 6 (9%) vs. trimethoprim 11 (16%); p= 0.205

Study Author Conclusions

Trimethoprim had a very limited advantage over cranberry extract in the prevention of recurrent UTIs in older women and had more adverse effects. Our findings will allow older women with recurrent UTIs to weigh up with their clinicians the inherent attractions of a cheap, natural product like cranberry extract whose use does not carry the risk of antimicrobial resistance or super-infection with Clostridium difficile or fungi.

InpharmD Researcher Critique

The difference in occurrence of recurrent UTI in both groups was not statistically significant potentially due to a limited sample size. Additionally, this trial was specific to older women with a history of UTI, thus, potentially limiting generalizability. Further evidence may be needed to assess the benefits of cranberry in younger adults. Also, this study utilized an extract from cranberry rather than juice. 



Table 10 References:
[18] McMurdo ME, Argo I, Phillips G, Daly F, Davey P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. J Antimicrob Chemother. 2009;63(2):389-395. doi:10.1093/jac/dkn489

A Randomized Trial to Evaluate Effectiveness and Cost Effectiveness of Naturopathic Cranberry Products as Prophylaxis Against Urinary Tract Infection in Women

Design

Randomized, double-blind, controlled trial

N= 150

Objective

To determine from a societal perspective, the effectiveness and cost-effectiveness of concentrated cranberry tablets, versus cranberry juice, versus placebo used as prophylaxis against lower urinary tract infection (UTI) in adult women

Study Groups

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)

Inclusion Criteria

At least 2 symptomatic, single organism, culture-positive UTIs in the prior calendar year; currently free of UTI on urinalysis and culture

Exclusion Criteria

Neurogenic bladder dysfunction, pregnancy, insulin-dependent diabetes, intermittent or indwelling catheterization, allergy to cranberry products, immunosuppressive disease, steroid use 

Methods

Eligible patients were randomized in blocks of 10 into one of three groups:

1. Placebo: one placebo tablet twice daily and 250 mL of placebo juice three times per day

2. Tablet: one tablet of concentrated cranberry juice (at least 1:30 parts concentrated juice) twice daily and 250 mL of placebo juice three times per day

3. Juice: 250 mL of pure unsweetened cranberry juice three times per day and one tablet of placebo twice daily

If symptoms of UTI occurred, culture-directed antibiotics were given for 3 days; then, prophylaxis was restarted.

Duration

Duration of intervention: 12 months

Outcome Measures

Symptomatic UTIs per year, patient-reported complications

Baseline Characteristics

 

 

 

 

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)  

Mean age, years (range)

43 (21-72) 40 (23-68) 44 (21-70)  

Premenopausal:postmenopausal

34:16 30:20 37:13  

Mean UTIs in the preceding year (range)

3.5 (2-5) 3.1 (2-4) 3.3 (2-5)  

Results

Endpoint

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)

p-value

At least 1 UTI during treatment

16 (32%)

9 (18%)

10 (20%)

< 0.05

Mean number of UTIs in a calendar year following treatment

0.72 0.39 0.3 < 0.05
Adverse Events

Common Adverse Events: placebo (headache n= 2 and mild nausea n= 2), tablet (mild nausea n= 4 and increased frequency of bowel movements n= 1), juice (symptoms of reflux n= 3)

Serious Adverse Events: N/A

Percentage that Discontinued due to Adverse Events: 2 patients in the juice group due to reflux 

Study Author Conclusions

Cranberry juice and cranberry tablets with increased fluid intake are more effective than fluid intake alone in preventing urinary tract infections in sexually active women with recurrent UTIs. 10-15% of women will experience fewer clinical lower urinary tract infections if cranberry products are added to the conservative measure of simply increasing fluid intake.

InpharmD Researcher Critique

This study has some limitations regarding the cranberry products that were used, as they were not regulated. Therefore the concentration of the active ingredients was not known. Additionally, researchers did not enroll pregnant women, and compliance was measured by self-reporting. 

The results did show that cranberry tablets are better tolerated than cranberry juice.

Table 11 References:
[19] Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol. 2002;9(3):1558-1562.

A Randomized Trial to Evaluate Effectiveness and Cost Effectiveness of Naturopathic Cranberry Products as Prophylaxis Against Urinary Tract Infection in Women

Design

Randomized, double-blind, controlled trial

N= 150

Objective

To determine from a societal perspective, the effectiveness and cost-effectiveness of concentrated cranberry tablets, versus cranberry juice, versus placebo used as prophylaxis against lower urinary tract infection (UTI) in adult women

Study Groups

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)

Inclusion Criteria

At least 2 symptomatic, single organism, culture-positive UTIs in the prior calendar year; currently free of UTI on urinalysis and culture

Exclusion Criteria

Neurogenic bladder dysfunction, pregnancy, insulin-dependent diabetes, intermittent or indwelling catheterization, allergy to cranberry products, immunosuppressive disease, steroid use 

Methods

Eligible patients were randomized in blocks of 10 into one of three groups:

1. Placebo: one placebo tablet twice daily and 250 mL of placebo juice three times per day

2. Tablet: one tablet of concentrated cranberry juice (at least 1:30 parts concentrated juice) twice daily and 250 mL of placebo juice three times per day

3. Juice: 250 mL of pure unsweetened cranberry juice three times per day and one tablet of placebo twice daily

If symptoms of UTI occurred, culture-directed antibiotics were given for 3 days; then, prophylaxis was restarted.

Duration

Duration of intervention: 12 months

Outcome Measures

Symptomatic UTIs per year, patient-reported complications

Baseline Characteristics

 

 

 

 

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)  

Mean age, years (range)

43 (21-72) 40 (23-68) 44 (21-70)  

Premenopausal:postmenopausal

34:16 30:20 37:13  

Mean UTIs in the preceding year (range)

3.5 (2-5) 3.1 (2-4) 3.3 (2-5)  

Results

Endpoint

Placebo (n= 50)

Tablet (n= 50)

Juice (n= 50)

p-value

At least 1 UTI during treatment

16 (32%)

9 (18%)

10 (20%)

< 0.05

Mean number of UTIs in a calendar year following treatment

0.72 0.39 0.3 < 0.05
Adverse Events

Common Adverse Events: placebo (headache n= 2 and mild nausea n= 2), tablet (mild nausea n= 4 and increased frequency of bowel movements n= 1), juice (symptoms of reflux n= 3)

Serious Adverse Events: N/A

Percentage that Discontinued due to Adverse Events: 2 patients in the juice group due to reflux 

Study Author Conclusions

Cranberry juice and cranberry tablets with increased fluid intake are more effective than fluid intake alone in preventing urinary tract infections in sexually active women with recurrent UTIs. 10-15% of women will experience fewer clinical lower urinary tract infections if cranberry products are added to the conservative measure of simply increasing fluid intake.

InpharmD Researcher Critique

This study has some limitations regarding the cranberry products that were used, as they were not regulated. Therefore the concentration of the active ingredients was not known. Additionally, researchers did not enroll pregnant women, and compliance was measured by self-reporting. 

The results did show that cranberry tablets are better tolerated than cranberry juice.

Table 12 References:
[20] Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol. 2002;9(3):1558-1562.

 

Effect of Oral Cranberry Extract (Standardized Proanthocyanidin-A) in Patients with Recurrent UTI by Pathogenic E.Coli: A Randomized Placebo-Controlled Clinical Research Study

Design

Randomized, placebo-controlled

N=72

Objective

To evaluate the effect of cranberry extract (PAC-A~ proanthocyanidin-A) on the in vitro bacterial properties of uropathogenic (E. coli) and its efficacy/tolerability in patients with subclinical or uncomplicated recurrent UTI (r-UTI)

Study Groups

Group 1 (n= 36)

Group 2 (n= 36)

Inclusion Criteria

Subclinical asymptomatic bacteriuria, or r-UTI, or not responding to antimicrobials

Exclusion Criteria

Pregnant or lactating, age <18 years

Methods

Patients were randomized into Group 1 or Group 2. Group 1 (PAC-A) received Cranpac, which contains 60mg PAC-A per capsule, 1 capsule twice a day for 12 weeks while Group 2 (placebo) received lactobacillus, which contains 400 million lactobacillus acidophilus per capsule, 1 capsule twice a day for 12 weeks. Adherence was assessed weekly

Duration

Enrollment: November 2011 to March 2013

Intervention: 12 weeks

Follow up: at 3 weeks, 6 weeks, and 12 weeks

Outcome Measures

Primary: change in the incidence of recurrent uncomplicated urinary tract infection (r-UTI):

Bacterial adhesion score (1 to 20 with 20 representing the highest adhesion rate between bacterial/urothelia cell)

Detection of bacterial growth and biofilm from urinary catheter samples grown on blood agar plates, incubated 24 hours at 35°C

Baseline Characteristics

 

Group 1 (n= 36)

Group 2 (n= 36)

 

Age, years

41.6 35.8  

Detection of bacterial growth 

33 36  

Bacterial adhesion score

2.11 1.81  

Detection of biofilm formation

8 6  

Results

Endpoint

Group 1 (n= 36)

Group 2 (n= 36)

p-Value

Detection of bacterial growth at 12 weeks

 8 35 <0.001

Bacterial adhesion score at 12 weeks

 0.28 2.14 <0.001

Detection of biofilm formation at 12 weeks

3 6 0.018

Adverse Events

Self-limiting conspiration occurred in one patient in each group

Study Author Conclusions

The overall efficacy and tolerability of standardized cranberry extract containing (PAC-A) were superior to placebo in terms of reduced bacterial adhesion... and in preventing recurrent UTI (dysuria, bacteria, and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose, and duration of PAC-A therapy in patients with recurrent UTI. Despite these limitations, the results of the present study appear to suggest a beneficial effect of cranberry when used prophylactically as a food supplement in selected patients with recurrent uncomplicated UTI.

InpharmD Researcher Critique

While this study was open to male and female patients, the baseline sex was not disclosed. Follow-up was limited to 12 weeks which may not provide a comprehensive overview of efficacy and safety.



Table 13 References:
[21] Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol. 2016;48(9):1379-1386. doi:10.1007/s11255-016-1342-8

 

Effect of Oral Cranberry Extract (Standardized Proanthocyanidin-A) in Patients with Recurrent UTI by Pathogenic E.Coli: A Randomized Placebo-Controlled Clinical Research Study

Design

Randomized, placebo-controlled

N=72

Objective

To evaluate the effect of cranberry extract (PAC-A~ proanthocyanidin-A) on the in vitro bacterial properties of uropathogenic (E. coli) and its efficacy/tolerability in patients with subclinical or uncomplicated recurrent UTI (r-UTI)

Study Groups

Group 1 (n= 36)

Group 2 (n= 36)

Inclusion Criteria

Subclinical asymptomatic bacteriuria, or r-UTI, or not responding to antimicrobials

Exclusion Criteria

Pregnant or lactating, age <18 years

Methods

Patients were randomized into Group 1 or Group 2. Group 1 (PAC-A) received Cranpac, which contains 60mg PAC-A per capsule, 1 capsule twice a day for 12 weeks while Group 2 (placebo) received lactobacillus, which contains 400 million lactobacillus acidophilus per capsule, 1 capsule twice a day for 12 weeks. Adherence was assessed weekly

Duration

Enrollment: November 2011 to March 2013

Intervention: 12 weeks

Follow up: at 3 weeks, 6 weeks, and 12 weeks

Outcome Measures

Primary: change in the incidence of recurrent uncomplicated urinary tract infection (r-UTI):

Bacterial adhesion score (1 to 20 with 20 representing the highest adhesion rate between bacterial/urothelia cell)

Detection of bacterial growth and biofilm from urinary catheter samples grown on blood agar plates, incubated 24 hours at 35°C

Baseline Characteristics

 

Group 1 (n= 36)

Group 2 (n= 36)

 

Age, years

41.6 35.8  

Detection of bacterial growth 

33 36  

Bacterial adhesion score

2.11 1.81  

Detection of biofilm formation

8 6  

Results

Endpoint

Group 1 (n= 36)

Group 2 (n= 36)

p-Value

Detection of bacterial growth at 12 weeks

 8 35 <0.001

Bacterial adhesion score at 12 weeks

 0.28 2.14 <0.001

Detection of biofilm formation at 12 weeks

3 6 0.018

Adverse Events

Self-limiting conspiration occurred in one patient in each group

Study Author Conclusions

The overall efficacy and tolerability of standardized cranberry extract containing (PAC-A) were superior to placebo in terms of reduced bacterial adhesion... and in preventing recurrent UTI (dysuria, bacteria, and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose, and duration of PAC-A therapy in patients with recurrent UTI. Despite these limitations, the results of the present study appear to suggest a beneficial effect of cranberry when used prophylactically as a food supplement in selected patients with recurrent uncomplicated UTI.

InpharmD Researcher Critique

While this study was open to male and female patients, the baseline sex was not disclosed. Follow-up was limited to 12 weeks which may not provide a comprehensive overview of efficacy and safety.



Table 14 References:
[22] Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol. 2016;48(9):1379-1386. doi:10.1007/s11255-016-1342-8

 

Effectiveness of Cranberry Capsules to Prevent Urinary Tract Infections in Vulnerable Older Persons: A Double-Blind Randomized Placebo-Controlled Trial in Long-Term Care Facilities

Design

Randomized, double-blind, placebo-controlled trial

N= 928

Objective

To determine whether cranberry capsules prevent urinary tract infection (UTI) in long-term care facility (LTCF) residents

Study Groups

High-Risk UTI Patients

Treatment Group: received cranberry capsule (n= 187)

Placebo Group: received matching controlled capsule (n= 189)


Low-Risk UTI Patients

Treatment Group: received cranberry capsule (n= 205)
Placebo Group: received matching controlled capsule (n= 207)

Inclusion Criteria

LTCF residents aged 65 and older

Exclusion Criteria 

Life expectancy of 1 month or less

Methods

Cranberry 500 mg capsules and placebo capsules were taken twice daily. Participants were stratified according to UTI risk (risk factors included long-term catheterization, diabetes mellitus, ≥1 UTI in preceding year).

Duration

12 months

Outcome Measures

Incidence of UTI according to a clinical definition

Baseline Characteristics

 

Cranberry

(n= 253)

Placebo
(n = 263)

 

Age, years

85

84

 

Female

74.3%

81%

 

Length of stay, months, n, median

17

19

 
 

Results

Endpoint

Cranberry
(n= 253)

Placebo
(n = 263)

p-value

Clinically Defined UTI

62.8%

84.8%

0.04

No difference in UTI incidence between cranberry and placebo was found in participants with low UTI risk (n = 412).

Adverse Events

None reported

Study Author Conclusions

In LTCF residents with high UTI risk at baseline, taking cranberry capsules twice daily reduces the incidence of clinically defined UTIs, although it does not reduce the incidence of strictly defined UTIs. No difference in the incidence of UTI was found in residents with low UTI risk.

InpharmD Researcher Critique

This study had a limited patient population once subjects were stratified into low-risk vs. high-risk UTI groups. Future studies should include a larger patient population with stricter inclusion/exclusion criteria.

 
Table 15 References:
[23] Griebling TL. Re: Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities. J Urol. 2015;193(1):152.

 

Effectiveness of Cranberry Capsules to Prevent Urinary Tract Infections in Vulnerable Older Persons: A Double-Blind Randomized Placebo-Controlled Trial in Long-Term Care Facilities

Design

Randomized, double-blind, placebo-controlled trial

N= 928

Objective

To determine whether cranberry capsules prevent urinary tract infection (UTI) in long-term care facility (LTCF) residents

Study Groups

High-Risk UTI Patients

Treatment Group: received cranberry capsule (n= 187)

Placebo Group: received matching controlled capsule (n= 189)


Low-Risk UTI Patients

Treatment Group: received cranberry capsule (n= 205)
Placebo Group: received matching controlled capsule (n= 207)

Inclusion Criteria

LTCF residents aged 65 and older

Exclusion Criteria 

Life expectancy of 1 month or less

Methods

Cranberry 500 mg capsules and placebo capsules were taken twice daily. Participants were stratified according to UTI risk (risk factors included long-term catheterization, diabetes mellitus, ≥1 UTI in preceding year).

Duration

12 months

Outcome Measures

Incidence of UTI according to a clinical definition

Baseline Characteristics

 

Cranberry

(n= 253)

Placebo
(n = 263)

 

Age, years

85

84

 

Female

74.3%

81%

 

Length of stay, months, n, median

17

19

 
 

Results

Endpoint

Cranberry
(n= 253)

Placebo
(n = 263)

p-value

Clinically Defined UTI

62.8%

84.8%

0.04

No difference in UTI incidence between cranberry and placebo was found in participants with low UTI risk (n = 412).

Adverse Events

None reported

Study Author Conclusions

In LTCF residents with high UTI risk at baseline, taking cranberry capsules twice daily reduces the incidence of clinically defined UTIs, although it does not reduce the incidence of strictly defined UTIs. No difference in the incidence of UTI was found in residents with low UTI risk.

InpharmD Researcher Critique

This study had a limited patient population once subjects were stratified into low-risk vs. high-risk UTI groups. Future studies should include a larger patient population with stricter inclusion/exclusion criteria.

 
Table 16 References:
[24] Griebling TL. Re: Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: a double-blind randomized placebo-controlled trial in long-term care facilities. J Urol. 2015;193(1):152.

Whole Cranberry Fruit Powder Supplement Reduces the Incidence of Culture-Confirmed Urinary Tract Infections in Females with a History of Recurrent Urinary Tract Infection: A 6-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Design

Multicenter, randomized, double-blind, placebo-controlled trial

N= 150

Objective

To investigate the effect of a whole cranberry fruit powder supplement on the incidence of culture-confirmed UTI in females with rUTI history

Study Groups

Whole cranberry powder (n= 75)

Placebo (n= 75)

Inclusion Criteria

Females aged 18–65 years; history of rUTI defined as ≥3 UTIs in the last year or ≥2 UTIs in the last 6 months; BMI >17.5 and <35 kg/m2

Exclusion Criteria

Microbial growth on urine culture ≥107 cfu/L 7 days prebaseline; history of >5 UTIs in last 6 months; use of antibiotics or antibacterial products within 28 days prior to baseline; regular use of Vaccinium containing products 28 days prebaseline; anatomical abnormalities of urinary tract; significant renal or urologic disease; pregnant and/or breastfeeding; significant cardiac, liver, gastrointestinal, metabolic disease or diabetes; immunocompromised or taking warfarin; alcohol abuse or illicit drug use

Methods

Participants at 5 Australian sites were randomized 1:1, stratified by site and age, to 500 mg whole cranberry powder (Pacran) or matched placebo once daily for 6 months. Urinalysis and cultures were obtained at baseline, months 3 and 6, and visits for UTI symptoms; symptomatic episodes received standard antibiotic treatment. Culture-confirmed UTI required >10⁸ CFU/L, with blinded review of positive/mixed cultures from routine visits. Suspected symptomatic UTI was defined as a symptom-associated unscheduled visit regardless of culture results. Adherence was assessed by capsule counts, and safety was monitored through visits and online surveys. Efficacy analyses included 145 participants and adjusted for age, site, sexual activity, and prior UTI frequency; no adjustment for multiple testing was performed.

Duration

6 months

Outcome Measures

Primary: Incidence of culture-confirmed UTI

Secondary: Incidence of symptomatic suspected UTI, incidence of individual symptoms of culture-confirmed UTI, time to first culture-confirmed UTI episode, number of culture-confirmed UTIs per participant, presence of individual uropathogenic species on culture, safety assessments

Baseline Characteristics  

Placebo (n= 75)

Whole cranberry powder (n= 75)
Age, years

34.2 (14.0)

35.1 (14.9)
Female

75 (100%)

75 (100%)
Postmenopausal

11 (14.7%)

16 (21.3%)
BMI, kg/m2

23.8 (3.8)

24.7 (4.9)
Sexually active 28 days prebaseline

61 (81.3%)

59 (78.7%)

Number of UTIs reported in previous 6 months

2.2 (0.8) 2.1 (0.8)
Results  

Placebo (n= 72)

Whole cranberry powder (n= 73) P-value
Incidence of culture-confirmed UTI

34.7%

17.8% 0.01
Incidence of symptomatic suspected UTI

38.9%

27.4% 0.08
Incidence of culture-confirmed dysuria

25.0%

16.4% 0.10
Incidence of culture-confirmed urinary frequency or urgency

31.9%

9.6% <0.01
Time to first culture-confirmed UTI episode (days)

69.7 (52.3)

91.9 (39.1) 0.01
Adverse Events

No safety concerns were reported. Incidence of treatment-related adverse events was generally low

Study Author Conclusions

Whole cranberry powder capsules reduce the incidence of culture-confirmed UTI and several other UTI-related outcomes in healthy females with rUTI history without impacting safety markers.

Critique

Blinded randomization, matched placebo, culture-based ascertainment, and sensitivity analyses strengthen the finding of fewer culture-confirmed UTIs with this specific cranberry preparation in otherwise healthy women with recurrent uncomplicated UTI. However, recruitment stopped at half the planned sample, the primary analysis excluded 5 randomized participants, and the per-protocol result was nonsignificant (RR 0.60; 95% CI 0.32–1.14; p=0.12); the absence of a significant reduction in suspected symptomatic UTIs and unadjusted multiple secondary comparisons temper the clinical interpretation.

Table 17 References:
[25] Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD. Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: A 6-month multicenter, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2025;121(4):932-941. doi:10.1016/j.ajcnut.2025.01.022

Randomized, placebo-controlled, double-blinded study of prophylactic cranberries use in women with recurrent uncomplicated cystitis

Design

Randomized, placebo-controlled, double-blinded clinical trial

N= 160

Objective

To assess the clinical utility of prophylactic use of high-dose proanthocyanidins (PACs) daily in women with a history of recurrent urinary tract infections (rUTIs)

Study Groups

Cysticlean™ 240 mg (n= 80)

Placebo (n= 80)

Inclusion Criteria

Adult, sexually active healthy women with recent history of rUTIs (≥2 UTIs in the past 6 months and/or ≥3 UTIs in the past 12 months) and a negative urine culture at enrollment

Exclusion Criteria

Pregnant or breastfeeding women, known allergy or intolerance to cranberry, use of cranberry products, vaginal estrogen, or other investigational drugs within 30 days prior to study entry, anatomic abnormalities of the urinary tract, recent surgery, acute or chronic renal failure, post-voiding residual >50 ml, nephrolithiasis, current use of anticoagulant medicines, presence of indwelling catheter, symptomatic vaginitis, spine diseases, and malabsorption

Methods

Participants were randomized to receive either Cysticlean™ 240 mg or placebo for 12 months. Urine samples, vaginal and rectal swabs were collected at initial and quarterly study visits. The primary endpoints were the number of UTIs and changes in Quality of Life (QoL), assessed by the SF-36 questionnaire.

Duration

November 2017 to August 2023

Outcome Measures

Primary: Number of UTIs, changes in Quality of Life (QoL)

Secondary: Number of women with at least three UTIs, asymptomatic bacteriuria events, changes in vaginal and gut E. coli colonization

Baseline Characteristics

 

Cysticlean™ 240 mg (n= 80) Placebo (n= 80) p-value

Age, years

41.0 (24.5) 39.5 (18.8) 0.062

BMI

24.2 (6.51) 23.9 (4.69) 0.572

Tobacco use

Smoker

Non-smoker

 

13 (16.25%)

67 (83.75%)

 

15 (18.75%)

65 (81.25%)

 

0.835

0.835

Menopause

Yes

No

 

28 (35%)

52 (65%)

 

16 (20%)

64 (80%)

 

0.052

0.052

Maternal history of UTIs

Yes

No

 

14 (17.5%)

66 (82.5%)

 

16 (20%)

64 (80%)

 

0.839

0.839

History of childhood UTIs

Yes

No

 

30 (37.5%)

50 (62.5%)

 

21 (26.25%)

59 (73.8%)

 

0.175

0.175

Number of sexual partner

0

1

2

 

3 (3.75%)

76 (95%)

1 (1.25%)

 

4 (5%)

75 (93.75%)

1 (1.25%)

 

0.928

0.928

0.928

Sexual frequency per week

≤1

2–3

≥4

 

19 (23.75%)

51 (63.75%)

10 (12.5%)

 

10 (12.5%)

48 (60%)

22 (27.5%)

 

0.025

0.025

0.025

Contraception types

Hormonal contraception

Spermicide

Condom

None

 

27 (33.75%)

20 (25%)

25 (31.25%)

8 (10%)

 

30 (37.5%)

18 (22.5%)

24 (30%)

8 (10%)

 

0.963

0.963

0.963

0.963

History of UTIs

3

4

5

6

 

70 (87.5%)

7 (8.75%)

2 (2.5%)

1 (1.25%)

 

75 (93.75%)

4 (5%)

1 (1.25%)

0

 

0.508

0.508

0.508

0.508

Antibiotics used

Quinolones

Cephalosporines

Aminoglycosides

Sulfamethoxazole/trimethoprim (SMX-TMP)

Penicillin

Nitrofurantoin

Combinations

None

 

37 (46.25%)

13 (16.25%)

1 (1.25%)

11 (13.75%)

1 (1.25%)

4 (5%)

12 (15%)

1 (1.25%)

 

38 (47.5%)

21 (26.25%)

0

6 (7.5%)

1 (1.25%)

4 (5%)

9 (11.25%)

1 (1.25%)

Results

A 2024 randomized, double-blind, placebo-controlled trial evaluated cranberry prophylaxis in 172 women with recurrent uncomplicated UTIs, of whom 160 were analyzed (80 per group).

Over 12 months, women receiving Cysticlean containing 240 mg of proanthocyanidins per capsule experienced 88 symptomatic UTI episodes versus 180 with placebo (adjusted incidence rate ratio [IRR] 0.49; 95% confidence interval [CI] 0.38 to 0.64; p< 0.001).

Three women (3.8%) receiving cranberry experienced ≥3 symptomatic UTIs compared with 41 (51.3%) receiving placebo (p<0.001). Median UTI-free survival was 7 months (95% CI 5.8 to 8.2) versus 4 months (95% CI 3.6 to 4.4), respectively, with an adjusted hazard ratio for symptomatic UTI of 0.34 (95% CI 0.23 to 0.50; p< 0.001).

Cranberry also reduced asymptomatic bacteriuria (IRR 0.54; 95% CI 0.40 to 0.73; p< 0.001), vaginal Escherichia coli colonization (IRR 0.71; 95% CI 0.58 to 0.87; p< 0.001), and rectal E. coli colonization (IRR 0.87; 95% CI 0.77 to 0.99; p= 0.032).

The SF-36 quality-of-life score increased from 87.22 at baseline to 88.3 at 12 months in the cranberry group (p< 0.001); corresponding placebo results were not reported. No adverse events were reported in either group.

Adverse Events

No adverse events were reported.

Study Author Conclusions

Daily use of Cysticlean™ 240 mg can prevent symptomatic rUTIs and improve general QoL in women with a history of rUTIs. Cysticlean™ can decrease asymptomatic bacteriuria episodes and number of E. coli strains in vaginal and gut microbiota.

Critique

Randomization, double blinding, placebo control, and 12-month follow-up support a preventive benefit for this specific cranberry formulation in women with recurrent uncomplicated UTIs. However, exclusion of 12 randomized participants, baseline differences in sexual frequency, optional culture confirmation, and inconsistent statistical reporting temper confidence in the effect magnitude; absent placebo SF-36 results also limit assessment of the claimed quality-of-life benefit.

Table 18 References:
[26] Tsiakoulias E, Gravas S, Hadjichristodoulou C, et al. Randomized, placebo-controlled, double-blinded study of prophylactic cranberries use in women with recurrent uncomplicated cystitis. World J Urol. 2024;42(1):27. Published 2024 Jan 12. doi:10.1007/s00345-023-04741-0